The failure of SkinBiotherapeutics (SBTX) to say why Stuart Ashman had been suspended before he resigned as CEO means that there can be no certainty as to the financial position of the company or the veracity of past claims made by Ashman and, as such, anyone buying shares is terribly brave. They may be rewarded they may not be, we shall see. But in thus void there are some crazy theories doing the rounds. A lawyer writes.
on Tom Winnifrith | Comments